Cat. No. 4799
Alternative Name: Ro 09-1978
Chemical Name: 5'-Deoxy-5-fluoro-N-[(pentyloxy)carb
Biological ActivityProdrug of 5-Fluorouracil (5-FU) (Cat. No. 3257). Selectively activated in tumor cells by thymidine phosphorylase; inhibits DNA synthesis upon conversion to 5-FU. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Desmoulin et al (2002) Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine. Drug Metab.Dispos. 30 1221. PMID: 12386128.
Shimma et al (2000) The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg.Med.Chem.Lett. 8 1697. PMID: 10976516.
Bhuyan et al (1972) Cell cycle phase specificity of antitumor agents. Cancer Res. 32 398. PMID: 4258018.
If you know of a relevant reference for Capecitabine please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Capecitabine from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Capecitabine, supplier, 5-Fluorouracil, prodrugs, 5-FU, DNA, synthesis, inhibitors, inhibits, inhbits, anticancer, Ro09-1978, chemotherapeutics, Tocris Bioscience, DNA, RNA and Protein Synthesis Inhibitor products
Find multiple products by catalog number
New Products in this Area
RAD51 recombinase inhibitorPCNA I1
PCNA inhibitorPladienolide B
mRNA splicing inhibitor; antitumorLin28 1632
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
Win a $1,000 travel grant
Bio-Techne is offering 10 travel grants of $1,000 for ISSCR 2017.